Stephen Y. Nakada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen Y. Nakada has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Yoshinari Ono
7 shared publicationsFred T. Lee
Department of Radiology, University of Wisconsin, Madison, WI, USA
4 shared publicationsTimothy D. Moon
Division of Urology, Department of Surgery, University of Wisconsin Medical School, Madison, WI, USA
4 shared publicationsGaurav Bandi
Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
3 shared publicationsSean P. Hedican
Division of Urology, Department of Surgery, University of Wisconsin Medical School, Madison, WI, USA
3 shared publicationsThomas F. Warner
University of Wisconsin-Madison, #TAB
3 shared publications
Latest Publications
- 16 May 2012
- Published by Springer Nature
- p. 97-99
Ureteroscopy: Opinion – No Access Sheath
- 2 December 2010
- Published by Springer Nature
- p. 667-672
Medical Management of Idiopathic Calcium Stone Disease
- 2 December 2010
- Published by Springer Nature
- p. 667-672
Medical Management of Idiopathic Calcium Stone Disease
- 2 February 2009
- Published by Wiley in BJU International
- Vol. 103 (4) , 524-528
Stone measurement by volumetric three‐dimensional computed tomography for predicting the outcome after extracorporeal shock wave lithotripsy
OBJECTIVE: To evaluate the efficacy of stone volume measured using a three‐dimensional (3D) reconstruction of preoperative non‐contrast computed tomography (NCCT) as an independent predictor of success after extracorporeal shock wave lithotripsy (ESWL) of upper urinary tract calculi. PATIENTS AND METHODS: We evaluated preoperative NCCT in 94 patients who had ESWL for solitary upper urinary tract calculi of 4–20 mm in diameter. Axial images were used to measure the skin‐to‐stone distance (SSD), Hounsfield Unit (HU) density and axial stone diameter. Stone volume was calculated on a volume‐rendered 3D image for each stone. Maximum stone length was determined by comparative measurements of each stone in coronal, sagittal and axial planes, and was also measured on a plain abdominal film before ESWL. For ESWL we used the DoliS lithotripter (Dornier Medical Systems, Marrietta, GA, USA). A plain film at 6 weeks was used to categorize patients as stone‐free (SF) or with residual stone. RESULTS: In all, 58 (62%) patients were SF and 36 (38%) had RS; the mean stone volume was significantly different between these groups (274 vs 464 µL, P = 0.002). Logistic regression analysis showed that stone volume was the strongest predictor of SF status ( P < 0.001), compared to peak HU ( P = 0.015), mean HU ( P = 0.04) and axial stone diameter ( P = 0.006). The body mass index, SSD and maximum stone length on NCCT or a plain film did not predict success. A stone volume of P < 0.001) with 72% of patients with a stone volume of 500 µL. CONCLUSION: Our study suggests that stone volume is an optimal predictor of SF status after ESWL of solitary upper urinary tract calculi.
- 2 February 2009
- Published by Wiley in BJU International
- Vol. 103 (4) , 524-528
Stone measurement by volumetric three‐dimensional computed tomography for predicting the outcome after extracorporeal shock wave lithotripsy
OBJECTIVE: To evaluate the efficacy of stone volume measured using a three‐dimensional (3D) reconstruction of preoperative non‐contrast computed tomography (NCCT) as an independent predictor of success after extracorporeal shock wave lithotripsy (ESWL) of upper urinary tract calculi. PATIENTS AND METHODS: We evaluated preoperative NCCT in 94 patients who had ESWL for solitary upper urinary tract calculi of 4–20 mm in diameter. Axial images were used to measure the skin‐to‐stone distance (SSD), Hounsfield Unit (HU) density and axial stone diameter. Stone volume was calculated on a volume‐rendered 3D image for each stone. Maximum stone length was determined by comparative measurements of each stone in coronal, sagittal and axial planes, and was also measured on a plain abdominal film before ESWL. For ESWL we used the DoliS lithotripter (Dornier Medical Systems, Marrietta, GA, USA). A plain film at 6 weeks was used to categorize patients as stone‐free (SF) or with residual stone. RESULTS: In all, 58 (62%) patients were SF and 36 (38%) had RS; the mean stone volume was significantly different between these groups (274 vs 464 µL, P = 0.002). Logistic regression analysis showed that stone volume was the strongest predictor of SF status ( P < 0.001), compared to peak HU ( P = 0.015), mean HU ( P = 0.04) and axial stone diameter ( P = 0.006). The body mass index, SSD and maximum stone length on NCCT or a plain film did not predict success. A stone volume of P < 0.001) with 72% of patients with a stone volume of 500 µL. CONCLUSION: Our study suggests that stone volume is an optimal predictor of SF status after ESWL of solitary upper urinary tract calculi.
- 1 September 2008
- Published by SAGE Publications in Journal of Endourology
- Vol. 22 (9) , 1885-1886
Rebuttal
- 1 September 2008
- Published by SAGE Publications in Journal of Endourology
- Vol. 22 (9) , 1885-1886
Rebuttal
- 17 July 2008
- Published by Wiley in BJU International
- Vol. 102 (3) , 404-415
Hand‐assisted radical laparoscopic nephrectomy
- 17 July 2008
- Published by Wiley in BJU International
- Vol. 102 (3) , 404-415
Hand‐assisted radical laparoscopic nephrectomy
- 5 March 2008
- Published by Wiley in BJU International
- Vol. 101 (9) , 1061-1062
TAMSULOSIN: URETERIC MOTILITY
- 5 March 2008
- Published by Wiley in BJU International
- Vol. 101 (9) , 1061-1062
TAMSULOSIN: URETERIC MOTILITY
- 17 October 2007
- Published by Wiley in BJU International
- Vol. 101 (4) , 459-462
Oncological outcomes of hand‐assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single‐institution study with ≥3 years of follow‐up
OBJECTIVE: To evaluate the intermediate‐term outcomes of hand‐assisted laparoscopic radical nephrectomy (HALRN) for clinically organ‐confined renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively reviewed patients who had HALRN for clinically organ‐confined RCC at the University of Wisconsin from 1996 to 2003. All patients with pathologically confirmed RCC and with ≥3 years of follow‐up were included in a retrospective chart review of variables before, during and after HALRN, as well as the clinical outcomes. RESULTS: In all, 75 patients had HALRN in the study period; their mean age was 59 years, body mass index 29 kg/m 2 , operative duration 227 min, estimated blood loss 130 mL, and none required conversion to open nephrectomy. The median time to first oral intake was 2.5 days and the median hospital stay 4 days. On pathological examination the mean tumour size was 5.8 cm; 70% were pT1, 26% pT2 and 4% pT3; 82% were clear cell, 9% papillary, 8% chromophobe and 1% collecting duct carcinoma. Of the 65 patients who had a follow‐up of ≥36 months (mean 46, range 36–117), the 3‐ and 5‐year disease‐free survival rate was 93.4% and 90.2%, respectively; the 3‐ and 5‐year cancer‐specific survival rate was 96.5% and 94.4%, respectively. CONCLUSION: Our study suggests that HALRN is a safe and minimally invasive treatment for managing clinically organ‐confined RCC, with good intermediate‐term oncological outcomes.
- 17 October 2007
- Published by Wiley in BJU International
- Vol. 101 (4) , 459-462
Oncological outcomes of hand‐assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single‐institution study with ≥3 years of follow‐up
OBJECTIVE: To evaluate the intermediate‐term outcomes of hand‐assisted laparoscopic radical nephrectomy (HALRN) for clinically organ‐confined renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively reviewed patients who had HALRN for clinically organ‐confined RCC at the University of Wisconsin from 1996 to 2003. All patients with pathologically confirmed RCC and with ≥3 years of follow‐up were included in a retrospective chart review of variables before, during and after HALRN, as well as the clinical outcomes. RESULTS: In all, 75 patients had HALRN in the study period; their mean age was 59 years, body mass index 29 kg/m 2 , operative duration 227 min, estimated blood loss 130 mL, and none required conversion to open nephrectomy. The median time to first oral intake was 2.5 days and the median hospital stay 4 days. On pathological examination the mean tumour size was 5.8 cm; 70% were pT1, 26% pT2 and 4% pT3; 82% were clear cell, 9% papillary, 8% chromophobe and 1% collecting duct carcinoma. Of the 65 patients who had a follow‐up of ≥36 months (mean 46, range 36–117), the 3‐ and 5‐year disease‐free survival rate was 93.4% and 90.2%, respectively; the 3‐ and 5‐year cancer‐specific survival rate was 96.5% and 94.4%, respectively. CONCLUSION: Our study suggests that HALRN is a safe and minimally invasive treatment for managing clinically organ‐confined RCC, with good intermediate‐term oncological outcomes.
- 15 August 2007
- Published by Wiley in BJU International
- Vol. 100 (4) , 798-801
Cryoablation of small renal masses: assessment of the outcome at one institution
OBJECTIVE: To report our 5‐year experience with laparoscopic and percutaneous cryoablation (LCA and PCA) for managing small renal masses. PATIENTS AND METHODS: We retrospectively analysed patients undergoing LCA and PCA between October 2000 and March 2006 at our institution. After approval from the Institutional Review Board, charts were reviewed retrospectively for variables during and after CA, and for clinical outcomes, the latter including the efficacy of the procedure in achieving overall, cancer‐specific and recurrence‐free survival. RESULTS: In all, 78 patients had CA of 88 small renal masses, by LCA in 58 and PCA in 20. The median American Society of Anesthesiology score was 3 and the mean body mass index was 30 kg/m 2 . All procedures were done under general anaesthesia, with a mean anaesthesia time of 220 min. The mean tumour size was 2.6 cm and the mean hospital stay was 2.1 days. At a mean follow‐up of 19 months, the overall, cancer‐specific and recurrence‐free survival rates were 88.5%, 100% and 98.7%, respectively. Four patients required a repeat treatment due to persistent disease and one had progression to locally advanced disease. Five patients had complications during CA and seven had complications afterward. CONCLUSION: This study suggests that CA is a safe, minimally invasive treatment option for patients with small renal masses, at the intermediate‐term follow‐up.
- 15 August 2007
- Published by Wiley in BJU International
- Vol. 100 (4) , 798-801
Cryoablation of small renal masses: assessment of the outcome at one institution
OBJECTIVE: To report our 5‐year experience with laparoscopic and percutaneous cryoablation (LCA and PCA) for managing small renal masses. PATIENTS AND METHODS: We retrospectively analysed patients undergoing LCA and PCA between October 2000 and March 2006 at our institution. After approval from the Institutional Review Board, charts were reviewed retrospectively for variables during and after CA, and for clinical outcomes, the latter including the efficacy of the procedure in achieving overall, cancer‐specific and recurrence‐free survival. RESULTS: In all, 78 patients had CA of 88 small renal masses, by LCA in 58 and PCA in 20. The median American Society of Anesthesiology score was 3 and the mean body mass index was 30 kg/m 2 . All procedures were done under general anaesthesia, with a mean anaesthesia time of 220 min. The mean tumour size was 2.6 cm and the mean hospital stay was 2.1 days. At a mean follow‐up of 19 months, the overall, cancer‐specific and recurrence‐free survival rates were 88.5%, 100% and 98.7%, respectively. Four patients required a repeat treatment due to persistent disease and one had progression to locally advanced disease. Five patients had complications during CA and seven had complications afterward. CONCLUSION: This study suggests that CA is a safe, minimally invasive treatment option for patients with small renal masses, at the intermediate‐term follow‐up.
- 1 January 2007
- Published by Elsevier
- p. 24-40
Laparoscopic Stapling and Reconstruction